Eisai Launches "Nitorol(R) Injection 5 mg Syringe" and "Nitorol(R) Continuous Intravenous Infusion 25 mg Syringe", First Nitric Acid Syringe Formulations Approved in Japan.

Tokyo, Japan, July 11, 2007 - (JCN Newswire) - Eisai Co., Ltd. announced the launch of "Nitorol(R) Injection 5 mg Syringe" and "Nitorol(R) Continuous Intravenous Infusion 25 mg Syringe" (generic name: isosorbide dinitrate), the first nitric acid syringe formulations approved for the treatment of acute cardiac failure and unstable angina in Japan. The new formulations will be available from July 12, 2007.

"Nitorol(R) Injection 5 mg Syringe" and "Nitorol(R) Continuous Intravenous Infusion 25 mg Syringe" are pre-filled syringes that contain the same solution as Eisai's existing ampoule formulation of "Nitorol(R) Injection 5 mg" (0.05% solution of isosorbide dinitrate). Unlike ampoules that require transferring the solution to syringes, the new formulations can be used with simple and easy preparation. Pre-filled syringes can also prevent foreign contamination of substances from getting into the solution.

"Nitorol(R)" has been contributing to the treatment of ischemic heart disease. By dilating arteries and veins, it reduces cardiac work loads. It also dilates coronary arteries and thereby improves the ischemic conditions. In addition, the rapid onset of action of "Nitorol(R) Injection" has demonstrated its utility in the treatment of acute heart failure and unstable angina, where fast treatment and reliable efficacy are vital.

Of the two newly introduced formulations, "Nitorol(R) Injection 5 mg Syringe" enables a shorter preparation process that is necessary in such occasions where a prompt injection of nitric acid is required in the catheter room. "Nitorol(R) Continuous Intravenous Infusion 25 mg Syringe" is designed to fit to precision programmable syringe pumps, supporting an early initiation of medical treatment.

Since the launch of "Nitorol(R) Injection 5 mg" in Japan in June 1986, Eisai has expanded the "Nitorol(R) Injection" product line by adding vial and soft bag formulations. The introduction of pre-filled syringe formulations will strengthen Eisai's commitment to make further contributions to improve usability and safety management in acute cardiac failure and unstable angina treatments.

About Eisai Co., Ltd.

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit http://www.eisai.co.jp.

Source: Eisai Co., Ltd.

Contact:

Eisai Co., Ltd.
Corporate Communications Department
Tel: [phone]

Japan Corporate News Network. All rights reserved.